Modulatory effects of bortezomib on host immune cell functions

Immunotherapy

Volumn 7, Issue 9, 2015, Pages 1011-1022

  Pellom, Samuel Troy ^a   Dudimah, Duafalia Fred ^a   Thounaojam, Menaka Chanu ^a   Sayers, Thomas Joseph ^b,c   Shanker, Anil ^a,d  

^a MEHARRY MEDICAL COLLEGE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

B cells; bortezomib; chemokine; cytokine; dendritic cells; immunity; inflammation; ligands; lymphocyte receptors; NK cells; T cells

Indexed keywords

BORTEZOMIB; CD34 ANTIGEN; DNAM 1 PROTEIN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEASOME; PROTEIN; PROTEIN BAX; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYTOKINE; UBIQUITIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL MATURATION; CELL PROLIFERATION; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; EPSTEIN BARR VIRUS INFECTION; GRAFT VERSUS HOST REACTION; HOST; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGLOBULIN PRODUCTION; IMMUNOTHERAPY; LIVER GRAFT; MALIGNANT NEOPLASTIC DISEASE; NATURAL KILLER CELL; NONHUMAN; OSTEOLYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTHESIS LOOSENING; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TOXIC SHOCK SYNDROME; TUMOR VOLUME; ULCERATIVE COLITIS; UPREGULATION; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; INNATE IMMUNITY; LYMPHOCYTE; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORTEZOMIB; CYTOKINES; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; LYMPHOCYTES; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 84946758547     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.66     Document Type: Review

References (72)

1. Pellom ST Jr, Shanker A. Development of proteasome inhibitors as therapeutic drugs. J. Clin. Cell Immunol. S5, 5 (2012).
2. Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat. Rev. Mol. Cell Biol. 6(1), 79-87 (2005).
3. Hershko A, Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 67, 425-479 (1998).
4. Xie Y. Structure, assembly and homeostatic regulation of the 26s proteasome. J. Mol. Cell Biol. 2(6), 308-317 (2010).
5. Driscoll JJ, Dechowdhury R. Therapeutically targeting the sumoylation, ubiquitination and proteasome pathways as a novel anticancer strategy. Target Oncol. 5(4), 281-289 (2010).
6. Li T, Ho L, Piperdi B et al. Phase II study of the proteasome inhibitor bortezomib (ps-341, velcade) in chemotherapynaive patients with advanced stage non-small cell lung cancer (NSCLC). Lung Cancer 68(1), 89-93 (2010).
7. O'Connor OA, Wright J, Moskowitz C et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-hodgkin's lymphoma and mantle cell lymphoma. J. Clin. Oncol. 23(4), 676-684 (2005).
8. Berges C, Haberstock H, Fuchs D et al. Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Immunology 124(2), 234-246 (2008).
9. Feng X, Yan J, Wang Y et al. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosisinducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells. Mol. Immunol. 47(14), 2388-2396 (2010).
10. Heider U, Rademacher J, Kaiser M, Kleeberg L, Von Metzler I, Sezer O. Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib. Clin. Lymphoma Myeloma Leuk. 10(2), 134-137 (2010).
11. Straube C, Wehner R, Wendisch M et al. Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells. Leukemia 21(7), 1464-1471 (2007).
12. Zinser E, Rossner S, Littmann L, Luftenegger D, Schubert U, Steinkasserer A. Inhibition of the proteasome influences murine and human dendritic cell development in vitro and in vivo. Immunobiology 214(9-10), 843-851 (2009).
13. Mulder A, Heidt S, Vergunst M, Roelen DL, Claas FH. Proteasome inhibition profoundly affects activated human B cells. Transplantation 95(11), 1331-1337 (2013).
14. Ames E, Hallett WH, Murphy WJ. Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition. Clin. Exp. Immunol. 155(3), 504-513 (2009).
15. Armeanu S, Krusch M, Baltz KM et al. Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clin. Cancer Res. 14(11), 3520-3528 (2008).
16. Chang CL, Hsu YT, Wu CC et al. Immune mechanism of the antitumor effects generated by bortezomib. J. Immunol. 189(6), 3209-3220 (2012).
17. Hallett WH, Ames E, Motarjemi M et al. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J. Immunol. 180(1), 163-170 (2008).
18. Lundqvist A, Yokoyama H, Smith A, Berg M, Childs R. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood 113(24), 6120-6127 (2009).
19. Seeger JM, Schmidt P, Brinkmann K et al. The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack. Cancer Res. 70(5), 1825-1834 (2010).
20. Shi J, Tricot GJ, Garg TK et al. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood 111(3), 1309-1317 (2008).
21. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 109(11), 4839-4845 (2007).
22. Jagannath S, Barlogie B, Berenson J et al. A Phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br. J. Haematol. 127(2), 165-172 (2004).
23. Chanan-Khan A, Sonneveld P, Schuster MW et al. Analysis of herpes zoster events among bortezomib-treated patients in the Phase III apex study. J. Clin. Oncol. 26(29), 4784-4790 (2008).
24. Blanco B, Perez-Simon JA, Sanchez-Abarca LI et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 107(9), 3575-3583 (2006).
25. Blanco B, Perez-Simon JA, Sanchez-Abarca LI et al. Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population. Haematologica 94(7), 975-983 (2009).
26. Shanker A, Brooks AD, Tristan CA et al. Treating metastatic solid tumors with bortezomib and a tumor necrosis factorrelated apoptosis-inducing ligand receptor agonist antibody. J. Natl Cancer Inst. 100(9), 649-662 (2008).
27. Kim JE, Jin DH, Lee WJ, Hur D, Wu TC, Kim D. Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells. Pharmacol. Res. 71, 23-33 (2013).
28. Jazirehi AR, Economou JS. Proteasome inhibition blocks NF-kappaB and Erk1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs. Mol. Cancer Ther. 11(6), 1332-1341 (2012).
29. Hideshima T, Ikeda H, Chauhan D et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 114(5), 1046-1052 (2009).
30. Cenci S, Mezghrani A, Cascio P et al. Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J. 25(5), 1104-1113 (2006).
31. Cascio P, Oliva L, Cerruti F et al. Dampening Ab responses using proteasome inhibitors following in vivo B cell activation. Eur. J. Immunol. 38(3), 658-667 (2008).
32. Schakel K, Kannagi R, Kniep B et al. 6-sulfo lacnac, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity 17(3), 289-301 (2002).
33. Schakel K, Mayer E, Federle C, Schmitz M, Riethmuller G, Rieber EP. A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (m-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur. J. Immunol. 28(12), 4084-4093 (1998).
34. Schakel K, Von Kietzell M, Hansel A et al. Human 6-sulfo lacnac-expressing dendritic cells are principal producers of early interleukin-12 and are controlled by erythrocytes. Immunity 24(6), 767-777 (2006).
35. Radtke F, Macdonald HR, Tacchini-Cottier F. Regulation of innate and adaptive immunity by Notch. Nat. Rev. Immunol. 13(6), 427-437 (2013).
36. Auderset F, Coutaz M, Tacchini-Cottier F. The role of Notch in the differentiation of CD4(+) T helper cells. Curr. Top. Microbiol. Immunol. 360, 115-134 (2012).
37. Amsen D, Blander JM, Lee GR, Tanigaki K, Honjo T, Flavell RA. Instruction of distinct CD4 T helper cell fates by different Notch ligands on antigen-presenting cells. Cell 117(4), 515-526 (2004).
38. Ogawa Y, Tobinai K, Ogura M et al. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in japanese patients with relapsed or refractory multiple myeloma. Cancer Sci. 99(1), 140-144 (2008).
39. Amsen D, Antov A, Flavell RA. The different faces of Notch in T-helper-cell differentiation. Nat. Rev. Immunol. 9(2), 116-124 (2009).
40. Iwakoshi NN, Lee AH, Vallabhajosyula P, Otipoby KL, Rajewsky K, Glimcher LH. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat. Immunol. 4(4), 321-329 (2003).
41. Tanaka S, Tsukada J, Suzuki W et al. The interleukin-4 enhancer CNS-2 is regulated by Notch signals and controls initial expression in NKT cells and memory-type CD4 T cells. Immunity 24(6), 689-701 (2006).
42. Subklewe M, Sebelin-Wulf K, Beier C et al. Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Hum. Immunol. 68(3), 147-155 (2007).
43. Hu W, Zheng RR, Cui HX, Yue D, Wang Y, Jiang YH. Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity. Asian J. Androl 14(5), 695-702 (2012).
44. Yong AS, Keyvanfar K, Hensel N et al. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood 113(4), 875-882 (2009).
45. Bosman MC, Schuringa JJ, Quax WW, Vellenga E. Bortezomib sensitivity of AML CD34+ cells can be enhanced by targeting the persisting activity of NF-kB and the accumulation of MCL-1. Exp. Hematol. 41(6), 530-538 (2013).
46. Soriani A, Zingoni A, Cerboni C et al. ATM-ATRdependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 113(15), 3503-3511 (2009).
47. Butler JE, Moore MB, Presnell SR, Chan HW, Chalupny NJ, Lutz CT. Proteasome regulation of ULBP1 transcription. J. Immunol. 182(10), 6600-6609 (2009).
48. Jardine L, Hambleton S, Bigley V, Pagan S, Wang XN, Collin M. Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands. Leuk. Lymphoma 54(1), 167-173 (2013).
49. Khan T, Stauffer JK, Williams R et al. Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors. J. Immunol. 176(10), 6302-6312 (2006).
50. Wang X, Feng X, Wang J et al. Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells. Anticancer Drugs 25(3), 282-288 (2014).
51. Berg M, Lundqvist A, Mccoy P Jr et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 11(3), 341-355 (2009).
52. Lundqvist A, Su S, Rao S, Childs R. Cutting edge: Bortezomib-treated tumors sensitized to NK cell apoptosis paradoxically acquire resistance to antigen-specific T cells. J. Immunol. 184(3), 1139-1142 (2010).
53. Iwata S, Yano S, Ito Y et al. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection. Int. J. Cancer 129(9), 2263-2273 (2011).
54. Mao X, Pan X, Peng X, Cheng T, Zhang X. Inhibition of titanium particle-induced inflammation by the proteasome inhibitor bortezomib in murine macrophage-like RAW 264.7 cells. Inflammation 35(4), 1411-1418 (2012).
55. Ramachandran S, Liaw JM, Jia J et al. Ischemia-reperfusion injury in rat steatotic liver is dependent on NFkappaB p65 activation. Transpl. Immunol. 26(4), 201-206 (2012).
56. Wilck N, Fechner M, Dreger H et al. Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition. Arterioscler. Thromb. Vasc. Biol. 32(6), 1418-1426 (2012).
57. Liu W, Ren HY, Dong YJ et al. Bortezomib regulates the chemotactic characteristics of T cells through downregulation of CXCR3/CXCL9 expression and induction of apoptosis. Int. J. Hematol. 96(6), 764-772 (2012).
58. Broxmeyer HE. Chemokines and chemokine receptors in hematopoiesis and immunology. Exp. Hematol. 34(8), 965-966 (2006).
59. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat. Immunol. 2(2), 123-128 (2001).
60. Sun K, Welniak LA, Panoskaltsis-Mortari A et al. Inhibition of acute graft-versus-host disease with retention of graftversus-tumor effects by the proteasome inhibitor bortezomib. Proc. Natl Acad. Sci. USA 101(21), 8120-8125 (2004).
61. Schmidt N, Gonzalez E, Visekruna A et al. Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis. Gut 59(7), 896-906 (2010).
62. Tilahun AY, Theuer JE, Patel R, David CS, Rajagopalan G. Detrimental effect of the proteasome inhibitor, bortezomib in bacterial superantigen-and lipopolysaccharide-induced systemic inflammation. Mol. Ther. 18(6), 1143-1154 (2010).
63. Lupov IP, Voiles L, Han L et al. Acquired STAT4 deficiency as a consequence of cancer chemotherapy. Blood 118(23), 6097-6106 (2011).
64. Liao ZJ, Ma WL, Meng W, Liang S, Meng FY, Zheng WL. Effect of velcade on the gene expression profiles of K562 cells: Study of its molecular mechanism. Nan Fang Yi Ke Da Xue Xue Bao 28(3), 373-376 (2008).
65. Tsapakidis K, Vlachostergios PJ, Voutsadakis IA et al. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells. Int. J. Urol. 19(6), 565-574 (2012).
66. Shanker A, Sayers T. Sensitizing tumor cells to immunemediated cytotoxicity. Adv. Exp. Med. Biol. 601, 163-171 (2007).
67. Chen F, Pisklakova A, Li M, Baz R, Sullivan DM, Nefedova Y. Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma. Cell Oncol. (Dordr.) 34(6), 545-551 (2011).
68. Xu D, Hu J, Xu S et al. DLL1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation. Leukemia 26(6), 1402-1405 (2012).
69. Blanco B, Sanchez-Abarca LI, Caballero-Velazquez T, Santamaria C, Inoges S, Perez-Simon JA. Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens. Leuk. Res. 35(10), 1412-1415 (2011).
70. Adams J, Palombella VJ, Sausville EA et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res. 59(11), 2615-2622 (1999).
71. Lightcap ES, Mccormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin. Chem. 46(5), 673-683 (2000).
72. Arastu-Kapur S, Anderl JL, Kraus M et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: A link to clinical adverse events. Clin. Cancer Res. 17(9), 2734-2743 (2011).